Moderna Inc. has already taken in $1.1 billion in deposits from governments ahead of the global launch of the coronavirus vaccine, according to the company’s press release. The announcement came as the company reported total revenues of $157.9 million revenues for Q3, up from $17.0 million the same period last year and above $77.5 million expectations.
- Moderna’s General Counsel and Corporate Secretary, Lori Henderson, will retire in 2021, and the company is looking for a replacement
- Moderna is in talks with the World Health Organization-backed COVAX initiative on a tiered proposal for its potential vaccine dubbed mRNA-1273
- Moderna already has supply agreements in North America, the Middle East, and other parts of the world.
- The company has completed enrollment for its 30,000-participant late-trial stage of the vaccine.
- In August, Moderna was charging between $32 and $37 per dose for its vaccine, but the company is in discussion for larger volume agreements that will lower the price
- Moderna reported a net loss of $233.6 million in Q3 or $0.59 per share, higher than expected loss of $0.43 per share, and above $123.2 million loss reported in Q3 2019.
Moderna stock is gaining. MRNA: NASDAQ is up 9.60%